MLYS: Congleton Jon discloses a sale

By AlphaYouPublished Oct 2, 2026Form 4

Stocks in this disclosure

Reported activity

Congleton Jon

Reporting filer

Congleton Jon reported Sale in Mineralys Therapeutics, Inc.: 75000 units of Common Stock, dated 2026-09-30. The full Form 4 contains 1 transaction entry.

Disclosed: Oct 2, 2026

Reported details

1 entry

All validated entries in this disclosure
Security	Owner	Date	Code	Action	Quantity	Price	Following holdings	Reporting delay	Filed terms and references
Common Stock	Congleton Jon	2026-09-30	S	Sale	75000	25.4622	528,621	2 days	Filed terms security Title: Common Stock transaction Date: 2026-09-30 transaction Form Type: 4 transaction Code: S equity Swap Involved: 0 id: F1 transaction Shares: 75000 transaction Price Per Share: 25.4622 id: F2 transaction Acquired Disposed Code: D shares Owned Following Transaction: 528621 direct Or Indirect Ownership: D

Common Stock

Owner: Congleton Jon
Date: 2026-09-30
Code: S
Action: Sale
Quantity: 75000
Price: 25.4622
Following holdings: 528,621
Reporting delay: 2 days
Filed terms and references: Filed terms
security Title: Common Stock
transaction Date: 2026-09-30
transaction Form Type: 4
transaction Code: S
equity Swap Involved: 0
id: F1
transaction Shares: 75000
transaction Price Per Share: 25.4622
id: F2
transaction Acquired Disposed Code: D
shares Owned Following Transaction: 528621
direct Or Indirect Ownership: D

Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.
Congleton Jon: Chief Executive Officer, Director.
The filing reports a Rule 10b5-1 trading plan.
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.0000 to $25.8201. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Original sources

SEC ownership filing

Prepared automatically from public filing data. Report a correction.

Security

Owner

Date

Code

Action

Quantity

Price

Following holdings

Reporting delay

Filed terms and references

Common Stock

Congleton Jon

2026-09-30

Sale

75000

25.4622

528,621

2 days

Filed terms

security Title: Common Stock
transaction Date: 2026-09-30
transaction Form Type: 4
transaction Code: S
equity Swap Involved: 0
id: F1
transaction Shares: 75000
transaction Price Per Share: 25.4622
id: F2
transaction Acquired Disposed Code: D
shares Owned Following Transaction: 528621
direct Or Indirect Ownership: D

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.

Congleton Jon: Chief Executive Officer, Director.

The filing reports a Rule 10b5-1 trading plan.

F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.0000 to $25.8201. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.